<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149676_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152623</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHHY2012FR122194</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20121231</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130118</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012FR122194</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>late due to CPO DS&amp;E</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>2013-SPON-039</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>2013-0009</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>2012-SPON-532</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>79</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Dyslipidaemia</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal failure chronic</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Nephropathy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Resuscitation</patientepisodename>
				<patientmedicalcomment>bullae boring</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Bullous eruption/ bullous lesions/diffuse bullous lesions with serous liquid inside</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Bullous eruption</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dermatitis bullous</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201208</reactionstartdate>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Blisters/appearance of oral bullae/one bulla on posterior and lateral pharyngeal wall</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blisters</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blister</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Urticaria on thorax and abdomen</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Urticaria</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Urticaria</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Upper limbs erythema with progressive spread to the whole body/diffuse papullar erythema</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Erythema diffuse</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Erythema</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Multiple itching lesions</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Itching</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pruritus</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypereosinophilia / eosinophilia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypereosinophilia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Eosinophilia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201208</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Oligoanuric renal failure/acute functional renal failure</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anuric renal failure</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal failure</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Lower limbs oedema up to knees</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Edema lower limb</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oedema peripheral</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Persistant arterial hypotension</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Arterial hypotension</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypotension</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121123</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Altered thyroid function</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Thyroid function abnormal</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Thyroid function test abnormal</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Positive with E.coli</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Escherichia coli test positive</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Escherichia test positive</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121123</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Anti-thyroid antibody</testname>
				<testresult>64</testresult>
				<testunit>IU/ml</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Anti-thyroid antibody</testname>
				<testresult>64</testresult>
				<testunit>IU/ml</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Biopsy skin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Blood creatinine</testname>
				<testresult>192</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Blood creatinine</testname>
				<testresult>132</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121206</testdate>
				<testname>Blood creatinine</testname>
				<testresult>106</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121213</testdate>
				<testname>Blood creatinine</testname>
				<testresult>131</testresult>
				<testunit>umol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Blood urea</testname>
				<testresult>23.8</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Blood urea</testname>
				<testresult>23.8</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Blood urea</testname>
				<testresult>14.3</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Blood urea</testname>
				<testresult>14.3</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121206</testdate>
				<testname>Blood urea</testname>
				<testresult>12.4</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121206</testdate>
				<testname>Blood urea</testname>
				<testresult>12.4</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Eosinophil count</testname>
				<testresult>3.56</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Eosinophil count</testname>
				<testresult>3.56</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Immunology test</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>NISISCO</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>20-818</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugdosagetext>1 DF, daily (160 mg vals and 12.5 mg hctz)</drugdosagetext>
				<drugdosageform>Film-Coated Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121123</drugenddate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>VALSARTAN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ATENOLOL </medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>100 mg, BID</drugdosagetext>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121123</drugenddate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ATENOLOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blister</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dermatitis bullous</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophilia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Erythema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Escherichia test positive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema peripheral</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thyroid function test abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urticaria</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>TAHOR</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>10 mg, one tablet daily</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Dyslipidaemia</drugindication>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121123</drugenddate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ATORVASTATIN CALCIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>GLUCOPHAGE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>500</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>500 mg, BID</drugdosagetext>
				<drugdosageform>Coated tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>METFORMIN HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DIAMICRON</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>032</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>2 DF, BID (40 mg)</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GLICLAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DOLIPRANE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121123</drugenddate>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PROFENID</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201207</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>KETOPROFEN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>TRAMADOL</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201207</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TRAMADOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>KETUM</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201207</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>KETOPROFEN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AERIUS</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201207</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DESLORATADINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PRAVASTATIN</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201207</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PRAVASTATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>AMOXICILLIN</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blister</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201207</drugstartdate>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMOXICILLIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012FR122194, is an initial spontaneous report from a health care professional via French Health Authorities (AN20120985) forwarded License partner by Ipsen pharma (2012-SPON-532) received on 31 Dec 2012, with follow-up report from other healthcare professional via French health authorities received on 31 Dec 2012 and on 18 Jan 2013. This report refers to a 79-year-old female patient. The patient's medical history included hypertension, dyslipidemia, non insulin dependent diabetes mellitus and vascular nephropathy with chronic renal failure. This polymedicated patient received Nisisco (valsartan, hydrochlorothiazide) tablet for hypertension arterial from an unknown date at a dose of 160/12.5 mg daily orally, atenolol (unknown manufacturer) for the treatment of an unknown indication from an unknown start date at a dose of 100 mg BID, Tahor (atorvastatin) for dyslipidemia at a dose of 10 mg one tablet daily orally, Glucophage (metformin hydrochloride) coated tablet for the treatment of type 2 non insulin dependant diabetes from an unknown date at a dose of 500 mg BID orally, Diamicron (gliclazide) tablet 80 mg for the treatment of type 2 non insulin dependant diabetes from an unknown date at a dose of 0.5 tablet mg BID that to say 40 mg BID, orally and Doliprane (paracetamol) for the treatment of an unknown indication from an unknown start date at an unknown dose. In Aug 2012, after starting the suspect drug the patient experienced bullous eruption and hypereosinophilia. Since Aug 2012, occurrence of upper limbs erythema with progressive spread to the whole body. The patient was hospitalized on 21 Nov 2012 for bullous dermatosis and oligoanuric renal failure. On 13 Nov 2012, her general physician (GP) prescribed ivermectin and Amoxicillin for 7 days for blisters. Then erythema spread and bullous lesions appeared requiring hospitalisation. Treatment was not recently modified. The patient had a dog and a budgerigar at home. On admission, eosinophilia and acute oligoanuric renal failure was diagnosed. On 23 Nov 2012, due to persistent arterial hypotension despite adequate fluid resuscitation she was transferred in an intensive care unit. The patient's clinical examination showed diffuse papullar erythema on thigh, abdomen, chest, shoulders and back, and diffuse bullous lesions with serous liquid inside, no Nikolski&#8217;s sign, no lesion on oral mucous membrane, lower limbs oedema up to knees, multiple itching lesions. The dermatologist advised on 26 Nov 2012 as probable bullous pemphigoid. On admission in a dermatologic unit on 27 Nov 2012, examination showed multiple tense bullous lesions on diffuse erythema on extension side of upper and lower limbs, back and face, urticaria on thorax and abdomen. The patient's complementary examinations include skin biopsy that showed auto-immune bullous dermatosis of dermal-epidermal junction suggesting bullous pemphigoid. Immunoblot assay results were expected. Anti-thyroid peroxidase antibodies were at 64UI/ml on 03 Dec 2012 (performed because altered thyroid function). CBEU (unspecified) positive with E.coli on 23 Nov 2012. Creatininaemia at 192 &#xc2b5;mol/L on 23 Nov 2012, at 132 &#xc2b5;mol/L on 30 Nov 2012, 106 &#xc2b5;mol/L on 06 Dec 2012, 131 &#xc2b5;mol/L on 13 Dec 2012. The patient's plasma blood urea nitrogen (BUN) was at 23.8 mmol/L on 23 Nov 2012, at 14.3 mmol/L on 30 Nov 2012, 12.7 mmol/L on 30 Nov 2012 and 12.4 mmol/L on 06 Dec 2012. The patient's eosinophils count was at 3.56 g/l on 23 Nov 2012. Infectious bovine rhinotracheitis (BHV), AHV, CHV serologies were negative. Local skin care was given as bullae boring and silver nitrate application. Topical corticoids on the whole body. After transfer in dermatologic unit, appearance of oral bullae recovering with local and systemic corticoids. Diagnosis hypothesis was given as atypical bullous pemphigoid, cicatricial pemphigoid or acquired epidermolysis bullosa. Ophthalmologic examination did not show eye lesions of bullous pemphigoid. Oral examination showed post bullous erosions of oral mucous membrane. One bulla on posterior and lateral pharyngeal wall at the oropharynx level. No cavum abnormality. Favorable cutaneous outcome with local and systemic corticoids. It was concluded that probable bullous pemphigoid and acute functional renal failure. Drug induced reaction non excluded. On an unspecified date, immunoblot assay results confirmed positive antibodies against bullus pemphigoid antigens BPAG2. No argument acquired bullous epidermolysis nor for paraneoplastic pemphigus. Outcome of the event bullous eruption was reported as condition improving, for hypereosinophilia was recovered and for blisters reported as condition unchanged while outcome for other events was not reported. The events bullous eruption, hypereosinophilia were considered as serious (hospitalization). Causality for the events bullous eruption, hypereosinophilia was reported as suspected. Seriousness and causality for other events were not reported.

Follow-up report from other healthcare professional via French health authorities received on 31 Dec 2012: Updated concentration and dosage regimen of Diamicron.

Follow up report received from other health care professional via French health authorities received on 18 Jan 2013: Suspect drug atorvastatine was updated to Tahor. Immunoblot test added and outcome of hypereosinophilia was changed to recovered. Narrative updated.</narrativeincludeclinical>
				<sendercomment>MAC Nisisco: Without information on the start date of suspect drug, a proper causality assessment cannot be performed. Case will be reassessed on receipt of follow-up information.

Based on Review of available reported data does not allow for a proper causality assessment. Reported events are not assessable

MAC for atenolol: Based on review of available reported data, the causal role of atenolol cannot be ruled out for bullous dermatitis. The causal role of atenolol for acute renal failure cannot be assessed. Underlying chronic renal failure, concomitant valsartan and atorvastatin can be possible alterantive explanation for acute renal failure.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
